Quest Diagnostics Incorporated (NYSE: DGX) reported a 40% dip in earnings for the first quarter of 2020 due to lower revenue and higher costs and expenses. The company has withdrawn its guidance for the full year 2020 due to the impact of the COVID-19 pandemic.
The pandemic is likely to impact the company’s ability to comply with applicable financial covenants, beginning as early as the end of the second quarter. The company has been in advanced discussions with its lead lender regarding an amendment to certain financial covenants of its unsecured revolving credit facility.
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated
The healthcare sector is going through a phase of consolidation, creating fresh opportunities for emerging companies in a market that is slowly recovering from the pandemic. Several pharmaceuticals firms have
Shares of American Airlines Group (NASDAQ: AAL) have gained 42% since the beginning of this year and 50% over the past 12 months. Despite this, there is a mixed sentiment